Diagnos Laboratorium Utama Tbk. vs Tripar Multivision Plus Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp224 (market cap 310.75B, 963.6K 24h volume), while Tripar Multivision Plus Tbk. trades at Rp199 (market cap 1.39T, 201.9K 24h volume). The key difference: Tripar Multivision Plus Tbk. is far larger — about 4.5× Diagnos Laboratorium Utama Tbk.'s market cap, and Diagnos Laboratorium Utama Tbk. is more actively traded (963.6K versus 201.9K). Which is the better fit depends on your goals.
| DGNS | RAAM | |
|---|---|---|
Market Cap | 310.75B | 1.39T |
Volume | 963.6K | 201.9K |
Lot | 9.64K | 2.02K |
Turnover | 217.67M | 40.78M |
Average Price | 225.89 | 201.96 |
Value | 217.67M | 40.78M |
Indicative Equilibrium Price | 226 | 199 |
Indicative Equilibrium Volume | 1K | 6 |
Trailing returns across standard periods
Latest headlines on both assets
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →PT Tripar Multivision Plus Tbk (“the Company”) was establishedbased on Deed of Establishment of Limited Liability Company No. 17 dated 6 December 1990 drawn up before Adlan Yulizar, S.H., notary in Jakarta.
Read more on RAAM →